Seer, Inc. will announce Q1 2025 financial results on May 13, 2025, with a live webcast at 1:30 PM PT.
Quiver AI Summary
Seer, Inc., a life sciences company specializing in proteomics, announced that it will release its financial results for the first quarter of 2025 on May 13, 2025. A conference call with company management will be webcast at 1:30 p.m. Pacific Time. The webcast can be accessed through the Investor section of Seer's website, where a replay will also be available afterward. Seer is known for its Proteograph Product Suite, which provides an integrated solution for deep proteomic analysis, designed to be efficient and user-friendly for laboratories. The products are intended for research purposes only and are not meant for diagnostic use. For additional information, visit their website.
Potential Positives
- Seer, Inc. plans to report its financial results on May 13, 2025, indicating transparency and regular communication with investors.
- The company is showcasing its innovative Proteograph™ Product Suite, which offers a unique solution for deep proteomic analysis, positioning it as a leader in the life sciences sector.
- The implementation of an easy-to-use workflow that employs widely adopted laboratory instrumentation may enhance customer adoption and usability of Seer's products.
Potential Negatives
- Although Seer, Inc. is announcing its upcoming financial results, they do not provide any preliminary financial data, which may indicate potential concerns about performance or growth.
- The press release emphasizes that the Proteograph Product Suite is for research use only and not intended for diagnostic procedures, which may limit its market applicability and revenue potential.
- The lack of any specific positive financial forecasts or growth metrics in the announcement may signal to investors a cautious outlook on the company's performance.
FAQ
When is Seer, Inc. reporting Q1 2025 financial results?
Seer, Inc. will report its Q1 2025 financial results on May 13, 2025.
What time is the conference call for Seer's Q1 results?
The conference call will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Where can I listen to Seer's conference call webcast?
The live audio webcast can be accessed in the Investor section of Seer’s website at investor.seer.bio.
What is Seer's Proteograph Product Suite?
Seer’s Proteograph Product Suite is an integrated solution for deep proteomic analysis using engineered nanoparticles and automation.
Is the Proteograph Product Suite intended for diagnostics?
No, Seer’s Proteograph Product Suite is for research use only and not intended for diagnostic procedures.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SEER Insider Trading Activity
$SEER insiders have traded $SEER stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $SEER stock by insiders over the last 6 months:
- OMID FAROKHZAD (CEO AND CHAIR) sold 8,068 shares for an estimated $18,044
- DAVID R. HORN (PRESIDENT & CFO) sold 3,550 shares for an estimated $7,939
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SEER Hedge Fund Activity
We have seen 26 institutional investors add shares of $SEER stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITIGROUP INC removed 760,501 shares (-66.1%) from their portfolio in Q4 2024, for an estimated $1,756,757
- ACUITAS INVESTMENTS, LLC removed 424,414 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $980,396
- MORGAN STANLEY added 372,199 shares (+176.1%) to their portfolio in Q4 2024, for an estimated $859,779
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 283,754 shares (-63.7%) from their portfolio in Q4 2024, for an estimated $655,471
- MAN GROUP PLC removed 185,509 shares (-91.9%) from their portfolio in Q4 2024, for an estimated $428,525
- RENAISSANCE TECHNOLOGIES LLC added 179,568 shares (+27.0%) to their portfolio in Q4 2024, for an estimated $414,802
- VANGUARD GROUP INC removed 161,727 shares (-6.9%) from their portfolio in Q4 2024, for an estimated $373,589
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit
www.seer.bio
.
Media Contact:
Patrick Schmidt
[email protected]
Investor Contact:
Carrie Mendivil
[email protected]
